Investigational drug · Phase 3
Velzatinib
Also called: GSK6042981
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Gastrointestinal Neoplasms, Gastrointestinal Stromal Neoplasms.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
8
Any phase or sponsor naming "Velzatinib"
First trial start
2026
Jul 27, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Velzatinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastrointestinal Neoplasms
- Gastrointestinal Stromal Neoplasms
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Velzatinib" as an intervention, largest first.
- A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07585266 · 800 participants (planned) · Start Jul 27, 2026 · Primary completion Aug 30, 2032
Drug: Velzatinib; Imatinib · For: Gastrointestinal Stromal Neoplasms
Sites: Scottsdale, Arizona; San Francisco, California; New Haven, Connecticut · 93 sites in all
- A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07218926 · 450 participants (planned) · Start Dec 3, 2025 · Primary completion May 30, 2028
Drug: IDRX-42; Sunitinib · For: Gastrointestinal Neoplasms
Sites: Phoenix, Arizona; Duarte, California; La Jolla, California · 156 sites in all
GlaxoSmithKlineGSK (GSK)
NCT07843641 · 72 participants (planned) · Start Oct 13, 2026 · Primary completion Jan 31, 2031
Drug: Velzatinib · For: Gastrointestinal Neoplasms
GlaxoSmithKlineGSK (GSK)
NCT07859735 · 40 participants (planned) · Start Nov 10, 2026 · Primary completion Apr 25, 2028
Drug: Velzatinib · For: Healthy Participants; Gastrointestinal Neoplasms
- A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy ParticipantsNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07862114 · 36 participants (planned) · Start Oct 16, 2026 · Primary completion Jan 12, 2027
Drug: Velzatinib; Cyclosporine and 1 more · For: Healthy Participants; Gastrointestinal Neoplasms
- A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on VelzatinibNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07867171 · 30 participants (planned) · Start Oct 23, 2026 · Primary completion Sep 9, 2027
Drug: Velzatinib · For: Healthy Participants; Gastrointestinal Neoplasms
GlaxoSmithKlineGSK (GSK)
NCT07689201 · 24 participants (planned) · Start Aug 17, 2026 · Primary completion Nov 29, 2027
Drug: Velzatinib · For: Gastrointestinal Neoplasms
Sites: Fukuoka, Japan; Hokkaido, Japan; Tokyo, Japan
GlaxoSmithKlineGSK (GSK)
NCT07825701
Drug: Velzatinib (GSK6042981) · For: Gastrointestinal Neoplasms
Newest research
PubMed records naming it or its code names, newest first.
- Gastrointestinal stromal tumors: can we do better than sunitinib in the second line?
Rutkowski P, Klimczak A · Expert Opin Pharmacother 2026
Also in development for Gastrointestinal Neoplasms
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.